Pharm-Olam is actively providing CRO services in support of COVID-19 clinical trials. As an Infectious Disease CRO and Vaccine CRO, we partner with governments and Sponsors to develop and test vaccines and therapeutics for drug approval and market readiness. Pharm-Olam is proudly supporting the fight against COVID-19 through direct support of Operation Warp Speed (OWS), as well as supporting other vaccines and therapeutics undergoing clinical trials.
In the past several years, Pharm-Olam has completed 114 Infectious Disease studies and served 28,395 patients across 2,140 sites. To put those numbers in perspective, 84% of PMs and 79% of CRAs currently on staff have worked in ID&V.
Pharm-Olam's teams have deep expertise in supporting studies in an ICU/critical care setting and navigating the common challenges encountered in this complex environment. That knowledge enables us to provide proactive and insightful CRO services for indications from Pneumonia to COVID-19 and everywhere in between.
Pharm-Olam has collaborated on over $778 million in government contracts, spanning several agencies, including CDC, DOD, and NIH. Pharm-Olam is also a member of the Medical CBRN Defense Consortium (MCDC) and was recently selected by BARDA to support Medical Countermeasure (MCM) development in a contract worth $250 million.
Pharm-Olam supports clinical trials in over 60+ countries. We help our Sponsors rapidly deploy their studies and maximize the subject recruitment period to deliver on-time and on-budget through our global reach and local insights.